Network Point-of-Care Glucose Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Network Point-of-Care Glucose Testing Market Trends and Insights

Hospital Network Integration: From Isolated Meters to Glycemic Command Centers

Hospitals are transitioning from standalone bedside testing to integrated glucose systems that directly input results into enterprise records. In April 2025, Abbott integrated FreeStyle Libre data into Epic via the Aura software platform. This move granted over 575,000 U.S. healthcare providers, catering to 280 million patients, seamless access to glucose data within their routine workflow. Once glucose data integrates with nursing documentation, billing, and treatment protocols, hospitals become reluctant to switch devices, even if competitors offer similar performance. Roche announced 24,000 new cobas pulse placements across EMEA by its 2026 Diagnostics Day, with a live U.S. launch in 2026, underscoring buyers' preference for systems that align with broader hospital software environments. Germany's KHZG funding program bolsters this trend, spotlighting connected point-of-care systems that resonate with hospital digitalization goals, catching the eye of procurement teams. 

Remote Monitoring in High-Risk Diabetic Patients: Expanding Bedside Testing Beyond the Bedside

Remote glucose monitoring is evolving from a temporary solution to a sustainable care model for high-risk inpatients. In May 2026, Glooko secured FDA 510(k) clearance for EndoTool IV Cloud, marking it as the first cloud-based inpatient insulin dosing platform approved for hospital use. This innovation eliminates the need for on-premise infrastructure, enabling centralized management across facilities. A multicenter study in Diabetes Care highlighted that real-time continuous glucose monitoring, paired with remote nursing oversight, curbed hypoglycemia in insulin-dependent inpatients without adverse effects. This allows hospitals to extend specialist supervision without overburdening bedside staff and emphasizes the growing importance of software platforms in procurement discussions. 

Expansion of Digital Diabetes Ecosystems: Devices as Entry Points, Not Endpoints

Connected glucose devices are increasingly recognized for their role in feeding data into expansive diabetes workflows, rather than just displaying readings at the bedside. Glooko advanced this approach in June 2026 by launching an insulin pump settings EHR integration, which incorporates basal schedules, insulin-to-carbohydrate ratios, and closed-loop status into EHR flowsheets. This integration allows clinicians to monitor glucose trends and insulin settings in a unified platform, minimizing the need to navigate multiple device portals. Hospitals now prioritize open integration over closed data models, reshaping supplier evaluations. Vendors supporting broad interoperability are advancing faster in hospital purchasing processes, solidifying the network point-of-care glucose testing market's connection to the development of digital diabetes ecosystems in hospitals and outpatient settings.

Reimbursement Support for Connected Glucose Monitoring: Unlocking Volume in Outpatient Transition Zones

Reimbursement backing is amplifying the value of connected glucose data, extending its significance beyond the initial inpatient stay. In the U.S., the rise in remote patient monitoring billing has increased interest in glucose systems capable of transmitting data post-discharge. This capability allows providers to integrate monitoring into documented follow-up workflows, ensuring a smooth transition for insulin-dependent patients returning to home management. In December 2025, Findex and Abbott Japan signed a data-linkage agreement connecting FreeStyle Libre 2 CGM data with the Medical Avenue patient guidance app and Claio medical data management system, enhancing continuity between hospital care and outpatient follow-up. 

Cybersecurity Review Burden: Compliance as a Market Entry Barrier

Connected glucose meters now face stricter compliance requirements before regulatory approval. The FDA’s final cybersecurity guidance, issued on June 27, 2025, updated Section 524B expectations, requiring software bills of materials, vulnerability disclosure plans, and detailed cybersecurity risk assessments in premarket submissions. These measures are critical as connectivity failures can erode trust in clinical outcomes. In December 2024, the FDA announced a Class I software correction for Nova Biomedical’s StatStrip glucose and glucose/ketone meters due to a software error that risked transmitting incorrect results during simultaneous wireless events. Smaller vendors often struggle with the time and costs needed to meet these demands, making market entry more challenging and favoring larger companies with stronger regulatory capabilities.

Interoperability Friction: The Hidden Cost of Multi-Vendor Hospital Environments

Many hospitals operate mixed-vendor point-of-care systems, creating integration challenges that exceed product claims. While a glucose meter may support connectivity, it often requires custom middleware setups and local validation to ensure smooth data transfer into laboratory or hospital information systems. A multicenter study on the cobas pulse system revealed that achieving reliable data flow across diverse IT environments required significant configuration and compliance validation during deployment.^{[1]National Center for Biotechnology Information, “Remote Glucose Monitoring Feasibility Study in Inpatients,” Diabetes Care via PMC, pmc.ncbi.nlm.nih.gov} These additional efforts increase time, costs, and coordination, prompting procurement teams to assess devices based on total implementation effort rather than just features or performance. Consequently, the network point-of-care glucose testing market heavily depends on hospitals’ IT readiness and integration capacity.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Accu-Chek Dominance Tested by Connectivity-First Challengers

Accu-Chek's Inform II, supported by Roche's navify POC Operations software, dominated the network point-of-care glucose testing market with a 48.40% share in 2025. This stronghold, particularly in European and North American hospitals, is reinforced by Roche's software, which supports over 100 device types and streamlines data management. Buyers now prioritize workflow platforms alongside testing devices, reflecting the industry's shift towards data management and compliance reporting. CareSens Expert Plus, featuring Wi-Fi, Ethernet, USB, and NFC connectivity, is the fastest-growing product, projected to expand at a 7.80% CAGR through 2031.

StatStrip, the only FDA-cleared meter for all critically ill patient sample types, continues to play a pivotal clinical role. Nova Biomedical strengthened this position in March 2025 with its next-generation platform, offering a Linux OS, RFID data entry, and a wider hematocrit range. HemoCue's Glucose 201+ maintains a steady presence in decentralized care, reporting 20 million tests in 2024 across 11,000 U.S. practices. Abbott's i-STAT 1 system remains critical in emergency settings, with FDA-cleared updates in August 2025 ensuring its relevance in multi-analyte testing. The market's leading systems integrate clinical functionality with hospital operations seamlessly.

By Modality: Handheld Devices Lead, But Wearables Are Rewriting the Clinical Logic

Handheld devices accounted for 42.87% of the network point-of-care glucose testing market in 2025, remaining the preferred choice for inpatient protocols due to their established presence and ease of integration into nursing routines. However, wearables are projected to grow at an 8.25% CAGR through 2031, driven by expanding clinical applications. A 2025 review highlighted the feasibility of real-time CGM with EHR integration in reducing fingerstick checks, though confirmatory testing remains standard in many settings.

Wearables are gaining traction as their clinical use cases expand. Abbott's CE Mark approval in May 2026 for its dual glucose-ketone biowearables highlights this trend. Benchtop devices, while the smallest modality, cater to lab-adjacent settings prioritizing throughput over portability. Japan's 2024 reimbursement pathway for inpatient real-time CGM signals faster wearable adoption. The competition is shifting from device form factors to the value of continuous, connected data in care decisions.

By Distribution Channel: Offline Retail Holds Share, But Digital Procurement Is Restructuring Hospital Purchasing

Offline retail held 45.45% of the network point-of-care glucose testing market in 2025, as hospitals relied on established distributor networks and direct contracts for regulated glucose systems. These purchases often involve validation, service agreements, and staff training, favoring distributors capable of long-term support. Online retail is projected to grow at a 6.69% CAGR through 2031, as facilities increasingly use digital tools for recurring supplies like strips and lancets. The market is split, with capital equipment moving through traditional channels and consumables finding easier access online.

Direct sales remain crucial for premium accounts, allowing major suppliers to bundle devices with software and support. Roche, Abbott, and Nova Biomedical excel in this model, as hospitals prefer comprehensive packages covering implementation and training. Smaller manufacturers face challenges in matching the extensive service structures of larger vendors. In emerging markets, digital procurement improves access to consumables, even as hospitals rely on traditional processes for initial system decisions. This dynamic shapes channel competition, balancing complex device adoption with swift supply fulfillment.

Geography Analysis

In 2025, North America accounted for 40.27% of the network point-of-care glucose testing market, making it the largest regional contributor. The region benefits from strong tertiary care infrastructure, high EHR adoption, and reimbursement systems that support connected monitoring. U.S. hospital networks often integrate glucose systems into broader IT and pharmacy workflows, favoring vendors with advanced integration tools. Roche’s 2026 launch of cobas pulse in the U.S. highlights the region's significant replacement and upgrade potential. Europe remains the second-largest market, with Germany leading due to KHZG funding, which drives adoption of connected point-of-care systems aligned with hospital digitalization strategies.

Asia-Pacific is projected to grow at a 7.45% CAGR through 2031, the fastest among all regions. Growth is driven by expanding hospital infrastructure, increasing diabetes care needs, and rising interest in connected monitoring in countries like China, India, Japan, and South Korea. Hospitals are increasingly adopting systems that support bedside testing and digital data integration. In 2025, Findex and Abbott Japan linked FreeStyle Libre 2 CGM data with patient guidance and medical data management systems in Japan, showcasing advancements in data connectivity across care settings.

The Middle East, Africa, and South America exhibit uneven growth due to budget constraints, fragmented IT systems, and slower device refresh cycles. However, urban hospital networks in Brazil and well-funded Gulf health systems present opportunities for connected glucose platforms. Multinational vendors play a key role in these regions, as hospitals often require significant implementation support. Market growth in these areas depends heavily on funding stability and digital readiness.